Allenex Board of directors evaluates the mandatory public offer from Xenella Holding AB
Godcup 7154 AB, undergoing name change to Xenella Holding AB (”Xenella”) has under the rules on mandatory public offers, on 23 November 2011, announced a public cash offer, to the shareholders of Allenex AB (publ) (”Allenex”), to sell all shares in Allenex to Xenella (the “Offer”). Xenella offers SEK 1.50 in cash for each share. The Offer does not include convertible instruments issued by Allenex. Xenella’s press release in the Swedish language on the Offer is available on Allenex’ website (www.allenex.se).
Xenella is a company controlled by Mohammed Al Amoudi and FastPartner AB (publ), Allenex’s two largest shareholders.
Xenella has indicated that the acceptance period will expire on 11 January 2012. The Board of directors of Allenex will, under NASDAQ OMX Stockholm’s rules on public offers on the stock market (the”Takeover Rules”), announce its view on the Offer and the reasons for this view no later than two weeks before the end of the acceptance period.
Since the board member Oscar Ahlgren is also managing director of Västra Hamnen Fondkommission AB, whose largest owner is Mohammed Al Amoudi, and since the board member Sven-Olof Johansson is also the managing director and largest shareholder in FastPartner AB (publ), these board members have been considered to be in a conflict of interest position. Hence, they will not participate in the evaluation of the Offer or deal with any issues relating to the Offer. As the board members in question will be considered to participate in the Offer, the Board of directors will, under article III.3 of the Takeover Rules, obtain a fairness opinion on the Offer from an independent expert as a basis for its evaluation. Allenex has appointed KPMG as financial advisor to obtain the fairness opinion.
Stockholm, 23 November 2011
Allenex AB (publ)
The Board of Directors
Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 20:10 (CET) on November 23, 2011.
For more information please contact:
Anders Karlsson, CEO Allenex AB, tel: +4670-918 0010, email: anders.karlsson@allenex.se
Or visit www.allenex.se
Allenex is a life science company that develops, manufactures, markets and sells high quality products and services that enables for safer transplantations with better results. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX).